Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recurrence-pattern-based Volume Versus Conventional-volume SBRT in Locally Advanced Pancreatic Cancer
NCT04699539Completed
- Sponsor
- Changhai Hospital
- Start
- Dec 2020
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Randomised, open-label trial in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Changhai Hospital. Primary endpoint: 1-year Progression Free Survival Rate. Started Dec 2020; status: completed.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04699539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699539.